Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.

doi:10.1001/jamanetworkopen.2022.32787

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.

JAMA network open - 1 Sept 2022

Whitworth Pat W, Beitsch Peter D, Patel Rakesh, Rosen Barry, Compagnoni Gia, Baron Paul L, Simmons Rache, Brown Eric A, Gold Linsey, Holmes Dennis, Smith Linda Ann, Kinney Michael, Grady Ian, Clark Patricia, Barbosa Karen, Lyons Samuel, Riley Lee, Coomer Cynara, Curcio Lisa, Ruiz Antonio, Khan Sadia, MacDonald Heather, Hughes Kevin, Hardwick Mary Kay, Heald Brandie, Munro Sandra B, Nielsen Sarah M, Esplin Edward D

Abstract excerpt

Importance: National Comprehensive Cancer Network guidelines currently recommend germline testing for high-risk genes in selected patients with breast cancer. The clinical utility of recommending testing all patients with breast cancer with multigene panels is currently under consideration. Objective: To examine the implications of universal testing of patients with breast cancer with respect to clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cohort Studies

Share to DNA Repair Mechanisms

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Germ Cells

Share to Prenatal Screening and Diagnostics

Source

Open in PubMed Open full text

Identifiers

PMID: 36136330
DOI: 10.1001/jamanetworkopen.2022.32787
PMCID: PMC9500554

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.PMID 36136330Read ↗

Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care.Semantic proximity Read ↗

Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.Semantic proximity Read ↗

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.Semantic proximity Read ↗

Universal genetic counseling in breast cancer patients significantly improves overall testing rates and improves completion rates in subpopulations.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.Semantic proximity Read ↗

Germline Genetic Testing After Cancer DiagnosisSemantic proximity Read ↗

Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.Semantic proximity Read ↗

Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?Semantic proximity Read ↗

Mainstream Germline Genetic Testing with Expanded Eligibility for Early Breast Cancer Patients in a Large Integrated Health System.Semantic proximity Read ↗

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.Semantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.